Development of a dengue exposure monitor

项目总结 世界上约40%的人口，即25亿人面临感染登革热的风险。这个 这种疾病是中南美洲、非洲和亚洲热带地区的地方病。疫情的爆发也 发生在美国南部，包括佛罗里达州和德克萨斯州，以及Hawiian FDA已经批准了一种单一的登革热疫苗。疫苗的安全性和有效性 取决于接受者以前是否接触过登革热病毒。 接受疫苗接种的血清阴性个人患严重登革热的可能性(特别是 2-4岁的儿童)强调需要一种可现场部署的设备来确定个人是否有 此前曾感染登革热病毒。有人担心，全民疫苗接种计划可能会 对生活在感染常态地区的人口产生有害影响。因此，一个快速、经济、 护理点(POC)化验，以确定个人是否已接触到病毒将是重要的。数据 这项检测将有助于医学界建立抗登革热疫苗接种方案。 Lynntech计划开发一种便携式、高度敏感和高度特异的诊断方法，能够 检测人体样本中的抗登革热抗体。将特别识别抗登革热抗体 并被高亲和力配体捕获，导致产生反映前 接触登革热病毒。Lynntech系统将提供一种直接的POC方法来评估 与以前接触登革热病毒有关的个体的血清学特征。全球需求 因为这样的检测增强了Lynntech产品的市场潜力。

PROJECT SUMMARY Approximately 40% of the world’s population, 2.5 billion people, are at risk of contracting dengue fever. The disease is endemic to tropical regions in Central and South America, Africa, and Asia. Outbreaks have also occurred in the southern portions of the United States, including Florida and Texas, as well as the Hawiian islands.The FDA has approved a single vaccine against dengue. Both safety and efficacy of the vaccine depend on whether or not the recipient has been previously exposed to the dengue virus. The potential for severe dengue disease in seronegative individuals receiving the vaccination (especially for children ages 2-4) underscores the need for a field-deployable device to determine if individuals have previously been infected by the dengue virus. There is a concern that a universal vaccination program could have deleterious effects on populations living in regions where infection is the norm. Thus, a rapid, economical, point-of-care (POC) assay to determine if an individual has been exposed to the virus will be significant. Data from this assay will assist the medical community in establishing an anti-dengue vaccination protocol. Lynntech proposes to develop a portable, highly sensitive, and highly specifc diagnostic that is capable of detecting anti-dengue antibodies in human samples. Anti-dengue antibodies will be specifically recognized and captured by high affinity ligands, resulting in the generation of an electrochemical signal reflecting pre- exposure to the dengue virus. The Lynntech system will offer a straightforward, POC means to assess the serological profile of individuals with respect to their previous exposure to the dengue virus. The global need for such an assay bolsters market potential for the Lynntech product.